
Please try another search
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Name | Age | Since | Title |
---|---|---|---|
Kenneth Anthony Cawkell | 74 | 2021 | Founder, Consultant, Corporate Secretary & Director |
Michael E. McFadden | 58 | 2021 | CEO & Director |
Len P. Mertz | 69 | 2021 | Independent Chairman |
Phillip Mertz | 40 | 2021 | Independent Director |
Jeffrey L. Cummings | 75 | 2021 | Member of Scientific Advisory Board |
Elaine Peskind | - | 2021 | Member of Scientific Advisory Board |
James E. Galvin | - | 2021 | Chair of Scientific Advisory Board |
Frank Conidi | - | 2021 | Member of Scientific Advisory Board |
Rajeev K. Bakshi | 66 | 2017 | Independent Director |
Mary Sano | - | 2021 | Member of Scientific Advisory Board |
Robert James Wills | 71 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review